IMC R117C
Alternative Names: IMC-R117CLatest Information Update: 23 Dec 2024
Price :
$50 *
At a glance
- Originator Immunocore
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer; Gastrointestinal cancer
- Preclinical Pancreatic cancer
Most Recent Events
- 26 Nov 2024 Phase-I/II clinical trials in Colorectal cancer in Italy (IV) (EUCT2023-508090-87-00)
- 26 Nov 2024 Phase-I/II clinical trials in Gastrointestinal cancer in Italy (IV) (EUCT2023-508090-87-00)
- 06 Nov 2024 Immunocore plans a phase I/II trial for colorectal and other gastrointestinal cancers in the second half of 2024